Use of intra-aortic balloon pump

Series
Cardiovascular
Status
Published
Date
Number of report
076

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for the use of intra-aortic balloon pump (IABP) in cardiogenic shock in Europe.

The following scenarios will be considered:

  • Use of IABP for treatment of cardiogenic shock in unstable angina or acute myocardial infarction;
  • Use of IABP in high-risk PCI for unstable angina or acute myocardial infarction.

The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of intra-aortic balloon pump (myocardial infarction and unstable angina, complicated by cardiogenic shock) include:

  • Abiomed (iPulse)
  • Insightra Medical (ULTRA 7FR)
  • Getinge (Cardiosave, CS)
  • Senko Medical (Corart)
  • Teleflex (AutoCAT2, AC3 Optimus)
  • Tokai Medical Products (7Fr-TAU)
  • Zeon Medical (Xemex)

Table of content is not available at the moment. Report is still ongoing.

28

Oct 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in September 2019 concern various types of devices, including orthopedic, cardiovascular devices, and hearing aids. A total of eighteen decisions were made.

Read more

01

Oct 2019

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including cardiovascular technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for cardiovascular devices in Europe.

Read more

23

Sep 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in July and August 2019 concern various types of devices, including orthopedic, cardiovascular, and blood glucose meters. A total of 29 decisions were made.

Read more

19

Aug 2019

Explanation about the coding of selective intravascular radiotherapy (SIRT) with microspheres labeled with holmium-166, and of creation of intracardiac septal defect with implantation of an interauricular implant (percutaneous transluminal) in Switzerland was released by SwissDRG on July 26, and July 31, 2019, respectively.

Read more

06

Aug 2019

The report presents a summary of the reimbursement situation for the use of intra-aortic balloon pump (IABP) in cardiogenic shock in Europe. The following scenarios are considered: use of IABP for treatment of cardiogenic shock in unstable angina or acute myocardial infarction; use of IABP in high-risk PCI for unstable angina or acute myocardial infarction. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

06

Aug 2019

In June 2019, the National Institute for Health and Care Excellence (NICE) published six new interventional procedure guidance, one new Medical technologies guidance for Endocuff Vision for assisting visualisation during colonoscopy, and two new MedTech innovation briefings (for Danis stent for acute oesophageal variceal bleeds, and The OPTIMIZER smart system for managing heart failure).

Read more

15

Jul 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in June 2019 concern various types of devices, including orthopedic, cardiovascular and diabetes devices, and cochlear implants. A total of 32 decisions were made.

Read more

26

Jun 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in May 2019 concern various types of devices, including orthopedic, cardiovascular and diabetes devices.

Read more

30

May 2019

The Federal Joint Committee (G-BA) has signed a further contract for scientific monitoring and implementation of a trial study for NYHA III heart failure therapy optimization by means of continuous blood pressure measurement and monitoring using an implanted sensor in the pulmonary artery.

Read more

23

May 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in April 2019 concern orthopedic devices, coronary stents, ventricular assist devices, remote monitoring systems in cardiovascular field, cochlear implants, bronchial thermoplasty device.

Read more

09

Apr 2019

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in March 2019 concern various types of devices, including orthopedic, cardiovascular (coronary stents), ENT and other products.

Read more

21

Mar 2019

The report presents a summary of reimbursement situation for cardiac pacemakers. Both single- and dual-chamber pacemakers are considered. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

Read more

13

Mar 2019

The French National Authority for Health (HAS) regularly publishes new (32 in total) decisions about add-on reimbursement for medical devices. The decisions made in February 2019 concern various types of devices, including multiple orthopedic, cardiovascular and other devices.

Read more
(we accept only company emails)